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PABPN1 gene therapy for oculopharyngeal
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Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant, late-onset muscle
disorder characterized by ptosis, swallowing difﬁculties, proximal limb weakness and nuclear
aggregates in skeletal muscles. OPMD is caused by a trinucleotide repeat expansion in the
PABPN1 gene that results in an N-terminal expanded polyalanine tract in polyA-binding
protein nuclear 1 (PABPN1). Here we show that the treatment of a mouse model of OPMD
with an adeno-associated virus-based gene therapy combining complete knockdown of
endogenous PABPN1 and its replacement by a wild-type PABPN1 substantially reduces the
amount of insoluble aggregates, decreases muscle ﬁbrosis, reverts muscle strength to the
level of healthy muscles and normalizes the muscle transcriptome. The efﬁcacy of
the combined treatment is further conﬁrmed in cells derived from OPMD patients. These
results pave the way towards a gene replacement approach for OPMD treatment.
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O
culopharyngeal muscular dystrophy (OPMD) is an
autosomal dominant, degenerative muscle disease
affecting about 1/100,000 people in Europe that usually
presents in the ﬁfth decade of life1. OPMD is mainly
characterized by progressive eyelid drooping, swallowing
difﬁculties (as the pharyngeal muscles are mostly affected) and
proximal limb weakness2.
Individuals affected by OPMD have a mutation in the PABPN1
gene, coding for polyA-binding protein nuclear 1 (PABPN1)3,
an ubiquitously expressed polyadenylation factor involved in
many biological processes4. PABPN1 stimulates the polydenylate
polymerase and controls the poly(A) tail length on RNA
transcripts5,6. PABPN1 regulates the use of alternative
polyadenylation sites7,8, which in turn affects mRNA levels and
stability. PABPN1 is also involved in the long non-coding RNA9
and small nucleolar RNA processing10, and in the nuclear
surveillance that leads to hyperadenylation and decay of RNA11.
Finally, two recent studies highlight the role for PABPN1 in
splicing regulation12,13. In OPMD, mutated PABPN1 has an
abnormal expansion of alanine-encoding (GCN)n trinucleotide
repeat in the coding region of exon 1 with 11–18 repeats instead
of the normal 10 present in unaffected individuals3,14.
The resulting protein (expPABPN1) is misfolded and prone to
aggregation in nuclear insoluble aggregates and this is considered
to be the main histopathological hallmark of the disease15,16.
However, like in many neurodegenerative diseases17,18, it is still
unclear whether these nuclear aggregates have a pathological
function or a protective role in OPMD as a consequence of a
cellular defence mechanism19–21.
No cure is currently available to arrest the disease. Surgical
cricopharyngeal myotomy is the only treatment available to
improve swallowing in these patients, but the pharyngeal
musculature still undergoes progressive degradation leading
to severe swallowing impairment, pulmonary infections and
choking2,22. Molecules potentially ameliorating the OPMD
phenotype (for example, trehalose and doxycycline) have been
tested in a mouse model of OPMD, where reduction in muscle
weakness was observed23,24. The use of trehalose is currently in
phase II clinical trial (NCT02015481 on clinicaltrials.gov). Other
pharmacological strategies currently under pre-clinical investi-
gation include antiprion drugs like 6-aminophenanthridine and
guanabenz, and targeting the expPABPN1 with intracellular
antibodies25–27. However, none of these strategies directly correct
the genetic defect of OPMD patients. A recent phase I/IIa clinical
trial that employed transplantation of unaffected autologous
myoblasts in combination with the cricopharyngeal myotomy
ameliorated the pathology of OPMD patients with a cell
dose-dependent improvement in swallowing28. However, the
injected cells still carry the mutation and thus may be susceptible
to the same OPMD phenotype.
The most commonly used murine model of OPMD, the
A17 mouse model, expresses a bovine expPABPN1 with 17
alanine residues under the control of the human alpha actin
muscle-speciﬁc promoter. In heterozygous mice, this model
recapitulates most of the features of human OPMD patients,
including progressive atrophy and muscle weakness associated
with nuclear aggregates of insoluble PABPN1 (refs 21,24,29).
Adeno-associated virus (AAV) is currently the most promising
viral vector for in vivo gene therapy applications due to its
non-pathogenicity, the natural efﬁcient infection in primates
for some serotypes and the negligible risk of insertional
mutagenesis30,31. Within the 4.7 kb vector packaging
capacity, AAV vectors can accommodate both transgenes and
shRNA/miRNA expression cassettes32. Recent clinical studies
based on localized or systemic administration of AAV vectors for
gene expression in humans have shown potential for the
treatment of human monogenic diseases, such as haemophilia,
retinal degeneration, metabolic disorders, muscular dystrophies
and degenerative diseases33–38. The use of AAV-mediated RNAi
therapeutics is receiving great attention in a wide range of
pathologies32, including dominant genetic disorders that involve
gain-of-function mechanisms39 and protein aggregate disorders
for which a silencing approach has shown some promise in
pre-clinical studies40,41.
Here we demonstrate a dual gene therapy approach in a mouse
model of OPMD by using RNA interference (RNAi) to inhibit
the expression of all endogenous (that is, both wild type and
expanded) PABPN1 and express a sequence-optimized normal
PABPN1 resistant to RNAi-induced cleavage. The simple
depletion of the endogenous (wild type and expanded) PABPN1
in mouse muscles effectively abolishes the nuclear aggregates, but
induces muscle degeneration. Furthermore, AAV-mediated
expression of a sequence-optimized human PABPN1 alone does
not signiﬁcantly improve the pathology either. On the contrary,
the simultaneous application of the two treatments prevents
muscle degeneration, markedly increases muscle strength,
normalizing the speciﬁc muscle force to that of unaffected
muscles, and essentially normalizes muscle gene expression
proﬁles. The efﬁcacy of the combined treatment was also veriﬁed
in cells derived from OPMD patients, where the expression of
transduced normal PABPN1 rescued the survival of cells where
the endogenous PABPN1 was downregulated. Overall, our data
indicate that PABPN1 aggregation induces, in OPMD, both a
gain of toxic function and a loss of physiological function and
strongly support the application of a dual gene therapy approach
as a novel treatment for OPMD in humans.
Results
PABPN1 knockdown and replacement validation in vitro.
DNA-directed RNA interference (ddRNAi) uses the cell’s own
transcriptional machinery to produce short double-stranded
hairpin RNA (shRNA), which when processed into siRNA can
degrade speciﬁc target mRNA. In order to ensure efﬁcient
knockdown of the PABPN1, three shRNA sequences (designated
sh-1, sh-2 and sh-3) were designed. Sequences sh-1 and sh-3
target PABPN1 mRNA in regions of conserved identity between
mouse, bovine and human species, while sh-2 speciﬁcally binds
bovine and human PABPN1. In order to provide a strong
knockdown of PABPN1 transcript levels, we assembled the coding
sequences for the three shRNAs into a tricistronic expression
cassette (called shRNA3X), with each hairpin RNA driven
by a different polymerase III promoter (U61, U69 and H1,
respectively) (Fig. 1a). As for in vivo muscle gene therapy
applications the use of AAV vectors is very efﬁcient, the
tricistronic shRNA3X cassette was cloned into an AAV backbone.
We also generated two separate plasmids harbouring a single-
stranded (ss) AAV expression cassette carrying either the human
codon-optimized PABPN1 sequence (optPABPN1) tagged with a
MYC epitope or the mutated expanded human PABPN1 com-
plementary DNA (cDNA) (expPABPN1) coding sequence tagged
with a FLAG epitope, both under the control of the muscle-
speciﬁc SPc5-12 promoter. With codon optimization, the
redundancy of the genetic code was exploited to largely modify
the nucleic acid sequence of PABPN1 (that is, 230 out of 921
nucleotides mismatches, corresponding to 25% difference) and
confer resistance of optPABPN1 to the expressed shRNA
sequences. To verify that shRNA3X was able to knock down
PABPN1 (both wild-type and mutated version of PABPN1) while
maintaining unaffected levels of optPABPN1, we transfected
HEK293T cells with the recombinant expression plasmid har-
bouring shRNA3X alone or used this plasmid in co-transfection
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experiments with the plasmids expressing expPABPN1 or
optPABPN1. A negative control shRNA, designed to target HBV
polymerase gene (HBVpol), was also transfected in parallel wells.
Samples were collected 72 h post transfection and PABPN1
expression levels were detected by western blot analysis. The
shRNA3X construct induced efﬁcient knockdown of PABPN1
even when expPABPN1 was co-expressed, achieving about 95%
knockdown in PABPN1 expression (Fig. 1b–d). Importantly,
detection of MYC-tag by western blot in samples treated with
plasmids expressing optPABPN1 demonstrated that shRNA3X
induced efﬁcient knockdown of the expPABPN1 protein, leaving
the expression of optPABPN1 protein unaltered (Fig. 1d).
Overall, these data demonstrate that the tricistronic construct
knocks down both wild-type and expanded PABPN1.
Furthermore, when co-delivered with shRNA3X, the human
sequence-optimized PABPN1 is resistant to degradation and
results in expression of a normal PABPN1.
PABPN1 knockdown and replacement in OPMDmouse muscle.
The corresponding AAV vectors were produced in HEK293T
cells by a double-transfection-based protocol and formulated for
in vivo injection. We selected serotype 8 and 9 AAV vectors based
on previous studies that demonstrated high levels of transduction
and expression in skeletal muscle42,43. To ensure robust PABPN1
knockdown, shRNA3X was delivered by self-complementary
AAV8 (scAAV-shRNA3X) that have been demonstrated to
achieve a more rapid and efﬁcient transgene expression than
their single-stranded counterparts44. The expression cassette for
optPABPN1 was packaged as a single-stranded construct into
AAV9 (ssAAV-optPABPN1) as this serotype has a better
packaging, resulting in higher titres (unpublished observations).
The A17 mouse model of OPMD overexpresses bovine
expPABPN1 along with the healthy murine version and
displays a progressive muscle atrophy and weakness associated
with nuclear PABPN1 aggregates21,24. AAVs were administered
by intramuscular injection in Tibialis anterior (TA) muscles of
10-12-week-old A17 mice at a concentration of either 2.5 1010
viral particles (vp) of scAAV-shRNA3X or 1.3 1011
ssAAV-optPABPN1 (respectively referred as shRNA3X and
optPABPN1), or as a combination of the two AAVs at the
same concentrations. Saline was injected in TA of age-matched
A17 and FvB (wild-type control strain) mice. Eighteen weeks post
injection, muscles were collected and RNA and proteins
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Figure 1 | The tricistronic construct efﬁciently silences endogenous normal and expanded PABPN1 without affecting optPABPN1 expression in vitro.
(a) Three constructs were cloned into pAAV vectors and used in this study: a tricistronic shRNA construct including hairpins sh-1, sh-2 and sh-3 driven
each by a different polymerase III promoter (U61, U69 and H1, respectively), the sequence-optimized PABPN1 (optPABPN1) driven by the SPc5-12 promoter
and tagged with a MYC-tag, and the human expanded PABPN1 (expPABPN1) driven by the SPc5-12 promoter and tagged with a FLAG-tag. (b) HEK293T
cells were transfected with 4mg per well of pAAV-shRNA3X in triplicate with or without AAV plasmids expressing expPABPN1 or optPABPN1.
Untransfected cells and cells transfected with AAV plasmid expressing shRNA for HBVpol were used as a control. Seventy-two hours post transfection,
samples were collected and PABPN1 was detected by western blot and quantiﬁed by densitometric analysis using ImageJ software. Transfection was
performed twice. PABPN1 expression in each condition was normalized by GAPDH expression level and then by the value of untransfected cells.
Transfection with a plasmid expressing shRNA3X induced efﬁcient PABPN1 knockdown even when expPABPN1 was co-expressed compared to
untransfected cells. The co-expression with optPABPN1 restored PABPN1 expression to the normal level. (c) Representative image of a western blot used
for these analyses. (d) FLAG is not detected when samples are transfected with shRNA3X. However, in samples prepared from cells transfected with
pAAV-opPABPN1, MYC-Tag is detected by western blot. Detection of MYC-Tag shows that optPABPN1 is resistant to degradation by shRNA3X in vitro. Data
are presented as mean±s.e.m., n¼4 (shRNA3XþoptPABPN1) or n¼6 (all the other groups). One-way ANOVA test with Bonferroni post-hoc test
*Po0.05, **Po0.01, NS, not signiﬁcant.
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extracted. Quantitative RT-PCR (qRT-PCR) showed a 35 and
45% decrease in endogenous PABPN1 expression in muscles
treated with either shRNA3X or shRNA3Xþ optPABPN1,
respectively, compared to saline-injected A17 muscles (Fig. 2a).
Western blot analysis detected a more profound inhibition
(that is, 80% knockdown) of expPABPN1 protein expression in
muscles treated with the shRNA3X as compared to saline-injected
A17 mice, and even greater levels of inhibition of PABPN1
protein levels (that is, approximately 90%) were noted upon
co-delivery of shRNA3X and optPABPN1 (Fig. 2b,c and
Supplementary Fig. 1a). Both qRT-PCR and western
blot further indicated that optPABPN1-MYC was successfully
expressed in muscles treated with optPABPN1 or the
combination of shRNA3X and optPABPN1 (Fig. 2d,e
and Supplementary Fig. 1b). We did not detect a difference
in MYC-tag quantiﬁcation between muscles treated with
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Figure 2 | Tricistronic shRNA delivered in vivo by AAV vectors efﬁciently downregulates endogenous PABPN1 without affecting optPABPN1
expression in vivo. Eighteen weeks after intramuscular AAV injections, TA muscles were collected and expression of PABPN1 was analysed. (a) qRT-PCR
analysis of PABPN1 mRNA normalized to the housekeeping gene RplP0 mRNA shows a statistically signiﬁcant decrease in PABPN1 expression in muscles
injected with shRNA3X and optPABPN1 compared with muscles injected with saline. (b) Western blot for PABPN1 expression shows that the treatments
with AAV-shRNA3X alone or in combination with AAV-optPABPN1 signiﬁcantly knock down the endogenous PABPN1. (c) Densitometric analysis of
western blot for PABPN1 detection shows statistically signiﬁcant reduction in protein expression when muscles are treated with shRNA3X (with or without
optPABPN1 expression) compared to the level of A17 muscles. PABPN1 expression was normalized to the relative vinculin expression. (d) qRT-PCR analysis
for optPABPN1 mRNA normalized to the housekeeping gene Rplp0 mRNA shows signiﬁcant expression in muscles where AAV-optPABPN1 was injected
(with or without shRNA3X co-expression). (e) Representative western blot for MYC-tag shows that the epitope is detected in all muscles treated with
AAV-optPABPN1 alone or in combination with AAV-shRNA3X. The arrow shows the band detected at the correct molecular weight. (f) Averages obtained
by densitometric analysis of MYC-tag detected in samples treated with AAV-optPABN1 only or with both AAV-shRNA3X and optPABPN1 viral vectors
indicates that shRNA3X does not affect optPABPN1 protein amount when co-expressed in muscles injected with both vectors. Two-tailed Student t-test,
n¼ 8, NS, not signiﬁcant. (g) Detection of PABPN1 inclusions (green) and Laminin (red) by immunoﬂuorescence in sections of treated muscles. Sections
were pre-treated with 1M KCl to discard all soluble PABPN1 from the tissue. Nuclei are counterstained with DAPI (blue). Bar, 200mm. (h) Quantiﬁcation of
percentage of nuclei containing INIs in muscle sections indicates that treatments with either AAV-shRNA3X or both AAV-shRNA3X and optPABPN1
signiﬁcantly reduce the amount of INIs to about 10% and 5%, respectively, compared to saline-injected A17. For a,c,d,h, n¼ 6 (saline-treated A17 or FvB
muscles) or n¼ 8 (all the other groups). Data are presented as mean±s.e.m. One-way ANOVA test with Bonferroni post-doc test **Po0.01, ***Po0.001,
NS, not signiﬁcant.
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optPABPN1 and muscles treated with shRNA3Xþ optPABPN1,
conﬁrming that in vivo optPABPN1 is resistant to the PABPN1
degradation provided by shRNA3X (Fig. 2e,f).
Quantitative PCR (qPCR) also conﬁrmed the expression of
shRNAs from the tricistronic construct in shRNA3X- and
shRNA3Xþ optPABPN1-treated muscles. Interestingly, a statis-
tically signiﬁcant difference in shRNA levels was noted between
muscles treated with shRNA3X only versus muscles treated with a
combination of both vectors (with a lower amount in the
shRNA3X-treated group) (Supplementary Fig. 1c). The effects of
PABPN1 knockdown were also assessed by analysing the amount
of insoluble aggregates in the myonuclei, the main pathological
hallmark of the disease, which are formed due to expPABPN1
expression. Insoluble nuclear aggregates were readily detected in
about 35% of myonuclei in A17 mice, while FvB myonuclei
contained virtually no aggregates. While the expression of
optPABPN1 did not modify the amount of insoluble aggregates
in A17 muscles, the treatment with either shRNA3X alone or the
combination of shRNA3X and optPABPN1 greatly decreased the
amount of myonuclei containing aggregates to 10 and 5% of
myonuclei, respectively (Fig. 2g,h).
These data show that shRNA3X delivered by AAV efﬁciently
downregulates PABPN1 in vivo and signiﬁcantly decreases
the amount of insoluble PABPN1 aggregates. Importantly,
a codon-optimized PABPN1, resistant to shRNA3X-induced
degradation, can be co-delivered and expressed by AAV.
PABPN1 knockdown alone has a detrimental effect in muscle.
Analysis of the shRNA3X-treated muscles group demonstrated
that depletion of endogenous PABPN1 by shRNAs induced
signiﬁcant muscle degeneration/regeneration, as indicated by the
increased presence of centrally nucleated ﬁbres (50% in
shRNA3X-treated muscles compared to 5% in saline-injected A17
mice) (Fig. 3a,c) as well as the increased levels of embryonic and
neonatal myosins (eMHC and neoMHC, respectively), which are
expressed when muscle ﬁbres regenerate (Fig. 3b,d). Notably, the
co-expression of optPABPN1 with shRNA3X in the A17 mice
was able to prevent the muscle ﬁbre degeneration and to maintain
the level of centrally nucleated ﬁbres as well as the low level of
MHC expressed in regenerating ﬁbres (Fig. 3a–d). In order to
analyse the effect of in vivo PABPN1 depletion in wild-type mice,
where only the normal endogenous level of PABPN1 is expressed,
TA muscles of C57BL/6 mouse were injected with 2.5 1010 vp
of scAAV-shRNA3X or a control AVV expressing green ﬂuor-
escent protein (ssAAV-GFP). Three months post injection,
massive muscle degeneration was observed, as evidenced by the
presence of more than 60% centrally nucleated ﬁbres, increased
embryonic myosin expression, decreased muscle weight and
impaired muscle strength in shRNA3X-treated muscles as com-
pared to GFP-treated TA muscles (Fig. 3e–j).
These data indicate that PABPN1 depletion in skeletal muscle
is detrimental and induces extensive muscle degeneration. The
co-expression of codon-optimized human PABPN1 prevents
the shRNA-induced muscle degeneration and normalizes the
muscle phenotype to that of untreated A17 mice.
Histological and functional improvement in OPMDmouse muscle.
In muscles co-treated with shRNA3X and optPABPN1, we
observed a signiﬁcant reduction in ﬁbrotic tissue compared with
the saline-injected A17 muscles as monitored by staining for
some of the main components of the extracellular matrix:
collagens I, III and VI and ﬁbronectin were detected by
immunoﬂuorescence and Sirius red staining (Fig. 4a,b and
Supplementary Fig. 2). Myoﬁbre cross-sectional area (CSA)
analysis also indicated that while injection of shRNA3X alone did
not modify the size distribution of myoﬁbres, the treatment with
optPABPN1 alone or in combination with shRNA3X markedly
increased the myoﬁbre CSA (Fig. 4c and Supplementary Fig. 3).
Before collecting the muscle tissues, TA muscle strength of
treated mice were analysed by in situ force measurement. No
difference was detected in resistance to eccentric contraction
between A17 and wild-type FvB mice, suggesting that the
expPABPN1 expression does not affect proteins associated to the
myoﬁbre sarcolemma (Supplementary Fig. 4). However saline-
injected muscles of A17 mice have a reduced muscle weight and
absolute maximal tetanic force compared with muscles of healthy
mice (Fig. 4d,e). Only the dual treatment with shRNA3X and
optPABPN1 signiﬁcantly increased the absolute maximal tetanic
force generated by the muscles while treatment with either
shRNA3X or optPABPN1 alone did not affect the muscle force.
Surprisingly, no substantial increase of muscle weight was
observed for any of the treatments (Fig. 4d) compared to saline-
injected A17 muscles. The normalization of the maximal force by
the muscle weight provides a measure of the muscle strength per
unit of tissue called speciﬁc maximal force (Fig. 4f). The speciﬁc
maximal force of muscles co-treated with the two vectors
shRNA3X and optPABPN1 was restored to the value of healthy
muscles, demonstrating that myoﬁbres of treated muscles were as
strong as those of wild-type mice. The concomitant reduction in
muscle ﬁbrosis and the small, but signiﬁcant, increase in myoﬁbre
CSA may explain the unchanged muscle weight and at least
partially account for the muscle strength improvement we
observed in treated muscles (Fig. 4f).
Overall these results show that while single treatments
inducing either the downregulation of PABPN1 or the expression
of normal PABPN1 protein do not ameliorate the pathology, the
combined treatment substantially improves the overall physiology
and increases muscle strength restoring the speciﬁc maximal
force to the wild-type level.
Gene expression proﬁle correction in OPMD mouse muscle.
Endogenous expPABPN1 expression in A17 mice substantially
modiﬁes the muscle transcriptome compared to wild-type
mice21,29. The effect of the gene therapy strategy on the A17 muscle
transcriptome was investigated using microarray analysis to identify
the number of genes dysregulated (41.5 fold change and Po0.05)
in the A17 model (Fig. 5a). As compared to saline-treated FVB
mice, 452 genes were upregulated (Fig. 5b), while an additional 413
of the sampled genes were downregulated (Fig. 5c). Treatment with
either the shRNA3X or the optPABPN1 resulted in only modest
normalization of the dysregulated genes, while the combined
treatment with shRNA3X and optPABPN1 vectors completely
normalized the dysregulated genes. In other words, of the original
865 genes that were dysregulated by more than 1.5 fold, only 12
genes remained signiﬁcantly different following the combined
shRNA3X and optPABPN1 treatment in the muscles of A17 mice
(Fig. 5a–c). This means that greater than 98% of deregulated
transcripts were normalized by the dual treatment in the muscles.
Overall these results show that the combined treatment leads to
a normalization of the muscle transcriptome.
Ex vivo correction of OPMD patient myoblasts. In order to
verify the beneﬁcial effect of the PABPN1 gene therapy strategy in
the context of the human target, we used a similar approach in
muscle cells derived from OPMD patients where expPABPN1 is
expressed. Because AAV is highly inefﬁcient at transducing
primary myoblasts in vitro, the expression cassettes from the
shRNA3X and optPABPN1 constructs were subcloned in lenti-
virus (LV) backbones that co-expressed the GFP reporter gene to
detect transduced cells. Constructs used included the tricistronic
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shRNA3X cassette, a construct expressing the control
HBVpol-shRNA, a construct expressing both the tricistronic
shRNA3X and optPABPN1, and ﬁnally a construct expressing the
control HBVpol-shRNA and optPABPN1 (Supplementary Fig. 5).
A strong knockdown of expPABPN1 was observed in HEK293T
cells after co-transfection of the shRNA3X LV construct with
expPABPN1 expression vector (Supplementary Fig. 6a). However,
PABPN1 knockdown in HEK293T cells was associated with a
strong reduction in cell viability after 2 weeks in culture
(Supplementary Fig. 6b,c). OPMD myoblasts were then trans-
duced with the corresponding LVs. GFP epiﬂuorescence was used
to monitor transduced cells. Similar to the transfection in
HEK293T cells, PABPN1 inhibition by shRNA3X was associated
to a substantial cell death of transduced cells: cell survival of
OPMD myoblasts treated with shRNA3X was severely affected
4 days after transduction and reduced to undetectable levels 10
days after treatment (Fig. 6a). On the contrary, cells transduced
with the dual cassette (shRNA3X and optPABPN1) were healthy
and proliferating 10 days after transduction (Fig. 6b), showing
that replacement of endogenous PABPN1 levels with optPABPN1
expression was sufﬁcient to rescue cell survival of the human
OPMD myoblasts.
These data conﬁrm that inhibition of endogenous PABPN1
expression is detrimental in a human cellular context and, most
importantly, in human myoblasts isolated from OPMD patients.
Notably, human optPABPN1 expression rescues cell survival
from the toxic effect of PABPN1 inhibition.
Discussion
No therapeutic intervention is currently available for patients
with OPMD, a dominant genetic disease characterized by the
formation of cellular inclusions as observed in other so
called ‘aggregopathies’ (for example, Parkinson’s, Alzheimers’s,
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Huntington’s diseases). Currently, OPMD patients are surgically
treated for the clinical manifestations of the disease, mainly by
blepharoplasty to correct the ptosis, and cricopharyngeal
myotomy to improve dysphagia. Like other protein aggregation
disorders, pre-clinical and clinical studies based on the inhibition
of aggregation formation or the clearance of existing aggregates
are also being developed for OPMD23,25–27,45. However, none of
these treatments directly corrects the genetic defect responsible
for the diseased phenotype in the OPMD patients. Gene therapy
holds the promise of providing a permanent cure for such
diseases that are untreatable or treatable but not curable with
conventional medicines46. As previously suggested by others47,
a strategy that could speciﬁcally impact the mutant allele would
be suitable for OPMD, but the small, abnormal 100% GC-rich
expansion in the mutant PABPN1 gene cannot easily be targeted
without impacting the wild-type PABPN1 function. As a
consequence, autosomal dominant inherited diseases such as
OPMD require a gene therapy approach that knocks down or
inhibits the pathogenic protein (that is, PABPN1) and also has
the ability to induce expression of a functional version of the
same gene. Here we used an AAV-based gene therapy approach
using a combination of DNA-directed RNA interference
(ddRNAi) to knock down the endogenous wild type and
mutant forms of the PABPN1 allele, and gene addition to
replace the transcript with a compensatory normal human
codon-optimized mRNA resistant to RNA interference-induced
cleavage. A similar pre-clinical approach has been used to restore
the functionality of rhodopsin in photoreceptors of the animal
model of Retinitis pigmentosa48,49. Here we show that this
approach is very effective for OPMD, a disease model of
aggregopathy, suggesting that a similar strategy could be
used for common neurological gain-of-function aggregopathies
such as Parkinson’s, Alzheimer’s or Huntington’s diseases. The
complexity of the central nervous system makes such neurological
disorders very difﬁcult diseases to treat, but successful gene
therapies have now been reported with the development of
integrating (LV) and non-integrating (AAV) vectors with
adequate tropisms46. Regarding muscular dystrophies, AAV is
currently the most promising viral vector for in vivo gene therapy
applications, but the treatment of most muscular dystrophies has
been hampered by the necessity to treat the whole musculature,
which encompasses 40% of the body weight. OPMD is
particularly suitable for such a gene therapy approach, as a very
restricted number of muscles are clinically affected at the onset of
the disease, making local intramuscular injections the most
realistic approach in clinical settings. The doses and volume of
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Figure 4 | In vivo co-administration of AAV-shRNA3X and AAV-optPABPN1 diminishes muscle ﬁbrosis and myoﬁbre atrophy and improves the
functionality of treated muscles. (a,b) Morphometric evaluation of Sirius red staining (a) or collagen VI immunostaining (b) in treated muscles of
30-week-old mice shows a signiﬁcant reduction in ﬁbrosis in muscles treated with AAVs expressing a combination of shRNA3X and optPABPN1 compared
to saline-treated muscles. (c) The average of myoﬁbre sizes per group shows that myoﬁbres of muscles treated with AAV-optPABPN1 only or in
combination with AAV-shRNA3X are larger than myoﬁbres of muscles treated with saline. (d) Eighteen weeks after AAVs injection no difference was
detected in the muscle weight of AAV-treated muscles compared to saline-injected TA of A17 mice. (e) Maximal force generated by TA muscles of treated
mice was measured by in situ muscle physiology, co-injecting AAV-shRNA3X and AAV-optPABPN1 signiﬁcantly increased the absolute maximal tetanic
force generated by TA muscles. (f) Normalization of maximal force by muscle weight provides a measure of the muscle strength per unit of skeletal muscle
called speciﬁc maximal force. The co-injection of the two AAVs normalized the speciﬁc maximal force of TA muscles to the level detected by wild-type
muscles. Data are represented as mean±s.e.m. a–c: n¼6 (saline-treated A17 or FvB muscles) or n¼ 8 (all the other groups). d–f: n¼8 (saline-treated A17
or FvB muscles) or n¼ 10 (all the other groups). One-way ANOVA test with Bonferroni post-hoc test, *Po0.05, ***Po0.001, NS, not signiﬁcant.
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viral vectors we used in this study are in a standard range for
intramuscular purpose in murine models, where a single injection
is performed to transduce the whole TA muscle. In the context of
potential human OPMD treatment, we envisage that AAV vectors
for knockdown and replacement would be distributed in several
points of the affected muscles by local intramuscular injection as
recently performed for autologous myoblasts (ClinicalTrials.gov
NCT00773227).
It has previously been demonstrated in cultures of myoblasts
that PABPN1 plays an essential role in their proliferation and
differentiation5. PABPN1 is considered an essential gene involved
in many biological pathways, and its expression is clearly crucial
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for cell survival50. This was conﬁrmed in Drosophila, where
lethality was observed in Pabp2 (homologue of human PABPN1)
mutants and rescued with a Pabp2 genomic transgene6. Our data
in mouse and patient muscle cells conﬁrm these observations,
as PABPN1 depletion induced drastic muscle degeneration,
myoﬁbre turnover in mice and cell death in patient myoblasts.
Interestingly, we also found that bringing a normal version of
PABPN1 in affected mice and, more importantly, in human
myogenic cells prevented the toxic effect of the PABPN1
knockdown, showing that lethal effects due to PABPN1
inhibition can be prevented and cell survival rescued.
Furthermore, we clearly demonstrated that in vivo PABPN1 is
required for muscle maintenance. Indeed, like in wild-type mice,
in A17 mice the in vivo depletion of PABPN1 in skeletal muscle is
detrimental and induces drastic muscle turnover. In these mice,
the shRNA3X construct effectively silenced both normal and
mutant endogenous PABPN1, and thus essentially depleted the
muscle from all endogenous protein.
The difference in shRNA levels and PABPN1 expression we
observed between muscles treated with shRNA3X only, and
muscles treated with both shRNA3X and optPABPN1, likely
reﬂects the turnover of the shRNA3X-expressing myoﬁbres in the
acute muscle degeneration/regeneration processes observed in the
group treated with shRNA3X only compared with the groups of
mice treated with both vectors (Fig. 3a–d). We propose that, in
muscles treated with shRNA3X only, new endogenous satellite
cells carrying the expPABPN1 activated in myoblasts proliferated
and fused to replace the shRNA3X-expressing myoﬁbres that
were cleared. During muscle regeneration myoblasts express
high-levels of PABPN1 (ref. 51), suggesting an essential role of
PABPN1 during tissue repair. Muscles co-expressing shRNA3X
and optPABPN1 were protected from the degeneration/
regeneration process (that is, from myoﬁbre turnover), and so
maintained higher level of shRNA molecules and lower levels of
expPABPN1. Our data on the combined treatment suggest that
the simple reduction of the protein and the consequent
abrogation of insoluble nuclear aggregates are not sufﬁcient to
rescue the pathology, and that at least a small amount of normal
protein needs to be expressed to allow cell survival and skeletal
muscle stabilization.
This is consistent with published data showing that the steady-
state level of PABPN1 (both protein and mRNA) is drastically
lower in skeletal muscle compared to other tissues51, which
possibly explains why even if the genetic mutation is present
body-wide only the skeletal muscle tissue manifests the clinical
signatures of the pathology. Accordingly, the level of PABPN1 in
normal muscles of FvB mice is almost undetectable21 (Fig. 2b and
Supplementary Fig. 1a).
It has been suggested that the presence of expPABPN1 nuclear
aggregates induces in OPMD a depletion of available normal
PABPN1. Therefore, the simple expression of a wild-type
PABPN1 may be enough to compensate for the PABPN1
segregated into the intranuclear aggregates. Interestingly, in our
study, the simple expression of normal PABPN1 alone was not
sufﬁcient to ameliorate the pathology in the A17 mouse model,
though we cannot exclude that this was due to expPABPN1 being
overexpressed in our mouse model. To the best of our knowledge,
there is only one study showing the effect of wild-type PABPN1
overexpression in OPMD in vivo models: Rubinsztein and
colleagues have shown that crossing a mouse overexpressing the
wild-type bovine version of PABPN1 (that is, a repeat encoding
including 10 alanine residues) with the A17 affected mouse
ameliorates the dystrophic pathology, reducing muscle cell death
due to apoptosis. In their study the amount of wild-type bovine
PABPN1 likely matched the amount of bovine expPABPN1 in
A17 mice52. However, the concurrent expression of the
endogenous wild-type murine version unbalanced the amount
of PABPN1 towards the normal protein. This ﬁnding conﬁrmed
that exceeding the mutated PABPN1 with a normal version
might potentially be enough in patient cells to see a small
improvement. Surprisingly, we did not achieve such a substantial
AAV-mediated overexpression in vivo of PABPN1, most likely
because the system is tightly regulated due to feedback
mechanisms that prevent the accumulation of a normal protein
in cells12, and only a small amount of functional protein can be
expressed. Importantly, the expression of PABPN1 in muscles
treated with both vectors likely derived only from the
optPABPN1, as shown by MYC detection. Expression of
optPABPN1 unbalanced the protein expression towards the
normal PABPN1 version and this was sufﬁcient to rescue the
phenotype in the absence of expPABPN1. Our gene therapy
treatment goes beyond the approach described by Rubinsztein
and colleagues as we also abrogated the intranuclear inclusions
(INIs), greatly ameliorating several aspects of the disease and
essentially normalizing the transcriptome of the A17 mouse to the
one of the FvB mice.
To summarize, while it is well known that a short alanine
expansion in the PABPN1 protein leads to OPMD, why such
mutation causes the pathology is still unknown17. One hypothesis
is that the alanine expansion causes a relative loss of function by a
decreased availability of normal PABPN1 at the protein level due,
at least partially, to its sequestration in nuclear aggregates. Such
loss of function is supported by the fact that decreased levels of
PABPN1 result in defective myogenesis51,53. The second
hypothesis is that the formation of nuclear aggregates induces a
toxic gain of function by trapping both the normal PABPN1 and
other molecules (proteins54–58 and RNA55,59–61) crucial for
several biological pathways. A pathological role of nuclear
aggregates is supported by the effects of anti-aggregation
therapies on improving OPMD phenotypes45,62, and data
showing that mutations in PABPN1 preventing aggregation do
not lead to muscle pathology in Drosophila model63. The mouse
model we used is characterized by a substantial overexpression of
expPABPN1 that leads to the formation of aggregates (Fig. 7a,b).
Our study shows that even by providing optPABPN1 there is no
reduction in intranuclear aggregates, no pathology improvement
and only a marginal change of muscle transcriptome (Fig. 7c).
Furthermore, even abolishing the aggregates by inhibiting the
endogenous PABPN1 results in no amelioration of the disease
(Fig. 7d). Only the combined treatment rescues the normal
PABPN1 expression and availability (Fig. 7e). These results
indicate that PABPN1 aggregation induces in the murine OPMD
model both a gain of function and a loss of physiological function.
Interestingly, the fact that the transcriptome of shRNA3X-treated
muscles is closer to the one of the FvB mice compared to the one
of optPABPN1-treated muscles suggests that the pathology—at
least in this mouse model—might be more dependent on a gain of
function than on a loss of function of PABPN1. Notably, the
changes in the transcriptome of AAV-shRNA3X treated muscles
do not translate into functional improvement due to the
substantial muscle damage.
Cell therapy is another appealing strategy to counteract
OPMD, as the treatment could be performed locally, thus
bypassing the issue of a systemic cell delivery. The local
administration of autologous myoblasts in the cricopharyngeal
muscle has been shown to improve swallowing function (ref. 28
and NCT00773227). While safe and associated to beneﬁcial
effects on a short term, autologous cells still harbour the
mutation. An ex vivo gene therapy approach aiming to correct
the genetic defect of myoblasts before the injection would be
required to guarantee a long-lasting effect. We transduced cells
derived from patient’s biopsies using a lentiviral vector carrying
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both the shRNA3X and the optPABPN1 cassettes on the same
backbone, and we showed that the combined strategy was
replicating at cellular levels the ﬁndings observed in vivo by AAV
vectors.
The positive outcome in a relevant human model of disease
suggests that the single bicistronic construct should also be tested
for the AAV-gene therapy strategy, as it would greatly reduce the
costs and efforts associated to the large-scale production of two
AAV vectors. Furthermore, it paves the way for the clinical
scenario where autologous myoblasts could be corrected ex vivo
before transplantation.
In conclusion, our study suggests that OPMD might be due to
both a gain of toxic function and a loss of function disease.
We show for the ﬁrst time that the in vivo gene therapy approach
for the treatment of OPMD, a dominant disease model of
aggregopathy, efﬁciently abolishes the formation of nuclear
aggregates, normalizes muscle transcriptome and improves
crucial hallmarks of the disease such as ﬁbrosis and muscle
atrophy, while increasing the muscle strength and normalizing
the speciﬁc maximal force (that is, the muscle functionality) to
that of unaffected muscles in a relevant animal model of the
disease. These ﬁndings suggest that a similar approach could
be used to treat other, more common, autosomal dominant
gain-of-function neurological diseases and pave the way for the
translation of this gene therapy strategy in clinical settings for
OPMD.
Methods
Cell lines and cell transfection and transduction. Human embryonic kidney
cells (HEK293T, ATCC, Manassas, USA) were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) containing 20mM HEPES, 10% foetal bovine serum
(FBS) and 2mM glutamine (PAA laboratories, Yeovil, UK) in a humidiﬁed 5% CO2
air atmosphere at 37 C. HEK293T cell line was not authenticated. Cells were
mycoplasma-free.
Human OPMD primary myoblasts isolated from a quadriceps muscle biopsy
were obtained and provided by Myobank-AFM, France64,65, which has an
authorization from the Ministry and the CNIL (Authorization for sample disposal
activity: No. AC-2013-1868). Muscle biopsy was obtained during surgical
procedure after informed consent. Brieﬂy, muscle biopsies were ﬁnely minced and
explants were plated onto non-coated Petri dishes in drops of foetal calf serum
(Invitrogen, Carlsbad, CA). Cells were cultured at 37 C in a humid atmosphere
containing 5% CO2. Once mononucleated cells had migrated out from the explants,
growth medium (that is, 199 Medium (Life Technologies) and DMEM (Life
Technologies) in a 1:4 ratio) supplemented with 20% foetal calf serum, 5 ngml l
human epithelial growth factor (Life Technologies), 0.5 ngml 1 bFGF, 0.2 mM
dexamethasone (Sigma-Aldrich), 50 mgml 1 fetuin (Life Technologies) and
5 mgml 1 insulin (Life Technologies) was added. Cell populations were trypsinized
when they reached 80% of conﬂuence.
HEK293T cells were seeded at 300,000 cells per well. The day after, 1 h before
transfection, the media was replaced with DMEM, 2% serum and no penicillin-
streptomycin (PS). Cells were transfected with a solution of DMEM without serum
and PS at a ratio of 125/1 DMEM/PEI (polyethyleneimine, linear MW 25,000)
using DNA plasmids for pAAV-shRNA3X alone or in combination with
pAAV-optPABPN1 or pAAV-expPABPN1. As a negative control, HEK293T cells
were transfected with the plasmid pAAV-HBVpol, which expresses an shRNA
against the HBVpol. Four micrograms per DNA plasmid was used per well. The
HEK293T cells were incubated at 37 C in DMEM with 2% FCS in the presence of
antibiotics for 72 h. Cells were collected and lysed for analysis by western blotting.
Human myoblasts were seeded at 50,000 cells per well into six-well plates.
The day after, cells were washed once with DMEM alone, and a 1ml solution of
DMEM, 10% foetal bovine serum and polybrene was added before transducing
cells at MOI 100 with lentiviral vectors. The day after, medium was changed and
cells were then cultured in growth medium.
Generation of AAV and LV plasmid constructs and vectors. Three shRNA,
called sh-1, sh-2, sh-3, were initially designed to bind common sequences in
human, mouse and bovine PABPN1. To generate a triple shRNA cassette
(shRNA3X), these shRNAs were cloned downstream of the U61, U69 and H1 RNA
polymerase III promoters, respectively. The shRNA3X construct was cloned into a
self-complementary pAAV2 backbone to generate pscAAV-shRNA3X.
Human PABPN1 fused with a MYC-tag (optPABPN1) and a Kozak sequence
was sequence-optimized by GeneArt (Waltham, USA). Both optPABPN1 and a
mutant human expanded PABPN1 tagged with FLAG (expPABPN1) were
subcloned into a ssAAV2 vector backbone downstream of SPc5-12 muscle-speciﬁc
promoter66 to generate pAAV-optPABPN1 and pAAV-expPABPN1. AAV vectors
expressing shRNA3X or optPABPN1 (scAAV2/8-shRNA3X and ssAAV2/9-
optPABPN1, respectively) were prepared with the standardized double transfection
protocol. Brieﬂy, HEK293T cells were seeded in roller bottles and cultured in
DMEM at 37 C and 5% CO2. When 50% conﬂuent, cells were transfected using
PEI with either pAAV-shRNA3X or pAAV-optPABPN1 and, respectively, pAAV
helper cap8 (pDP8.ape) or pAAV helper cap9 plasmids (pDP9rs), and cultured in
roller bottles for 3 more days. Cells were lysed and recombinant pseudotyped AAV
vector particles were puriﬁed by iodixanol (Sigma-Aldrich) step-gradient
ultracentrifugation. The copy number of vector genomes was quantiﬁed by dot blot
hybridization and qPCR. The titres of the AAV batches used for the in vivo
application in this study were 1 1012 vp per ml for scAAV2/8-shRNA3X and
5.2 1012 vp per ml for ssAAV2/9-optPABPN1. For local injection in C57BL/6
mice control muscles were dosed with a single-strand AAV8-CMV-GFP
(ssAAV8-GFP) prepared using the protocol described for the other AAV vectors.
LV vectors expressing the same triple shRNA cassette (shRNA3X) driven by the
same RNA polymerase III promoters (U61, U69 and H1) were produced by
subcloning the expression cassette into a LV backbone together with a PGK-eGFP
expression cassette. The optPABPN1 sequence was subcloned into a LV vector
backbone where its expression was driven by SPc5-12 muscle-speciﬁc promoter
(Supplementary Fig. 5). Unconcentrated and concentrated LVs were produced
using HEK293T transfection65 Brieﬂy, HEK293T were cultured in DMEM high
glucose-containing medium supplemented with 10% foetal calf serum (37 C and
5% CO2). Lentiviral production was performed using a DNA/CaCl2 transfection
mix of a combination of the lentiviral vector, packaging plasmids and an envelope
expressing plasmid. Forty-eight hours post transfection, the medium containing
LVs was collected and spun down by centrifugation to remove cell debris. The
supernatant was ﬁltered (0.22mm) to get a ﬁnal clariﬁed solution. The ﬁltrate was
transferred into ultracentrifuge tubes and centrifuged at 4 C for 1 h 30min at
22,000 r.p.m. Lentiviral pellets were suspended in PBS and left at 4 C for at least
2 h (up to overnight). The ﬁnal clear viral solution was aliquoted and stored at
 80 C until use. Titration was performed by qPCR and ﬂux cytometry.
In vivo experiments. A17.1 transgenic mice (called here A17) express expanded
(17 alanines) PABPN1 cDNA construct under the control of the human skeletal
actin promoter and present progressive muscle weakness21,24. A17 mice and
wild-type (WT) FvB controls were generated by crossing the heterozygous carrier
strain A17 with the FvB background mice and genotyped by PCR for bovine
PABPN1 4 weeks after birth. C57Bl6 mice were obtained from Janvier Labs.
Animals were housed with food and water ad libitum in minimal disease facilities
(Royal Holloway, University of London). Ethical and operational permission for
in vivo experiments was granted by the RHUL Animal Welfare Committee and the
UK Home Ofﬁce, and this work was conducted under statutory Home Ofﬁce
regulatory, ethics, and licensing procedures, under the Animals (Scientiﬁc
Procedures) Act 1986 (Project Licence 70/8271). All treated mice were used for the
analyses. Brieﬂy, twenty 10–12-week-old A17 male mice were randomized based
on body weight and age and anaesthetized with isoﬂurane, and 2.5 1010 vp of
scAAV8-shRNA3X or 1.3 1011 vp of ssAAV9-optPABPN1 or the two vectors in
combination were diluted in 50 ml saline and intramuscularly administered into
both TA muscles in ﬁve mice for each condition (that is, ﬁve mice per experimental
group). Also, ﬁve of these A17 mice and ﬁve age-matched male FvB mice were
injected with saline in both TA muscles as negative and healthy controls,
respectively. Three 10–12-week-old C57BL6 male mice were injected in the
TA muscles with 2.5 1010 vp of scAAV8-shRNA3X or with 2.5 1010 vp of
ssAAV8-GFP in the contralateral TA as a control. At 18 weeks post injection, all
mice were anaesthetized with pentobarbital, and in situ TA muscle physiology was
performed. After analysis mice were weighed, killed and TA muscles were excised
from tendon to tendon, weighed and frozen in liquid nitrogen-cooled isopentane.
Muscle force measurement. Mice were anaesthetized using a pentobarbital
solution (intraperitoneally, 60mg kg 1) and contractile properties of TA muscles
were analysed by in situ muscle electrophysiology67. A blind analysis was
performed by the investigator. The knee and foot were ﬁxed with clamps and the
distal tendons of the muscles were attached to an isometric transducer (Harvard
Bioscience) using a silk ligature. The sciatic nerves were proximally crushed and
distally stimulated by a bipolar silver electrode using supramaximal square wave
pulses of 0.1ms duration. All data provided by the isometric transducer were
recorded and analysed using the PowerLab system (4SP, AD Instruments).
All isometric measurements were made at an initial length L0 (length at which
maximal tension was obtained during the tetanus). Response to tetanic stimulation
(pulse frequency: 75–150Hz) was recorded and the maximal force was determined.
For the measurement of muscle susceptibility to contraction-induced injury,
muscles were stimulated at 150Hz nine times. The stimulation-stretch cycle was
repeated every 45 s. At each contraction, muscles were lengthened by 0.15mm
corresponding to 15% of muscle length. Maximum force was measured after each
eccentric contraction and expressed as a percentage of the initial maximal force.
After contractile measurements, muscles were collected, weighed to calculate the
speciﬁc maximal force and frozen in isopentane cooled in liquid nitrogen and
stored at  80 C.
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qRT-PCR analysis. Total RNA was extracted from skeletal muscles using Trizol
(Invitrogen) according to the manufacturer’s instructions. RNA quality and purity
was determined using a ND-1000 NanoDrop spectrophotometer (NanoDrop
Technologies) and RNA (50–250 ng for muscle biopsies, 1–3mg for cell pellet) was
reverse transcribed using M-MLV reverse transcriptase (Invitrogen) according to
the manufacturer’s instructions. cDNA was used for qPCR reaction using SYBR
green mix buffer (LightCycler 480 Sybr green I Master) in a total of 9 ml reaction
volume. PCR reactions were performed as follows: 8min at 95 C followed by 50
cycles: 15 s at 95 C, 15 s at 60 C and 15 s at 72 C. The speciﬁcity of the PCR
products was checked by melting curve analysis using the following programme:
65 C increasing by 0.11 C s 1 to 97 C. The expression level of each mRNA was
normalized against murine RPLP0 mRNA (large ribosomal protein, subunit P0)
expression. Expression levels were calculated according to the DDCt method.
The sequences of primers used for RT-PCR and for qRT-PCR are included as
Supplementary Note 1.
Affymetrix mouse 2.0 ST arrays expression proﬁling. Quality control was
performed on total RNA extracted from mouse muscles using a Nanodrop and
Bioanalyzer (Agilent Technologies, Santa Clara, CA). RNA quality and purity
was determined using a ND-1000 NanoDrop spectrophotometer (NanoDrop
Technologies) followed by Quality Control analysis (Agilent 2100 Bioanalyzer,
Eukaryote Total RNA Nano assay, Agilent RNA 6000 Nano Kit, Agilent RNA
Nano LabChip) to determine the RNA integrity number (RIN, 28S/18S ratio).
Ninety nanograms of total RNA per sample was further processed using the
GeneChip WT PLUS Reagent Kit for whole transcript expression proﬁling
(Affymetrix, Santa Clara, CA). The sense strand ss cDNA was puriﬁed, fragmented
and labelled using DNA-labelled reagent and then hybridized overnight onto the
Mouse 2.0 ST arrays (100 or 81/4-Format). Prior to hybridization, the arrays were
registered on GeneChip Command Console Software (AGCC) (Affymetrix, Santa
Clara, CA). After the overnight hybridization, the arrays were washed and stained
using the GeneChip Hybridization on a Fluidics 450 station (Affymetrix, Santa
Clara, CA) and then scanned using the AGCC scan control software (Affymetrix,
Santa Clara, CA). The raw data ‘cel’ ﬁles were analysed using Bioconductor
(R software68). Raw signal intensities were quantile normalized with oligo
package68 and differential expression analysis was performed using the limma
package69. Principal component analysis was performed using prcomp function
and rgl package.
Quantiﬁcation of shRNA 1-3 copy number in muscles. For shRNA copy number
analysis, custom RT and quantitative PCR assays were developed for each hairpin.
Standard curves used for absolute quantiﬁcation were generated for each sequence
utilizing a 10-fold dilution series (108–102 copies) of HPLC-puriﬁed RNA oligos
(Sigma-Aldrich). Diluted RNA oligo standards and 50 ng of puriﬁed RNA from
each TA muscle sample were reverse transcribed into cDNA using miScript II RT
kit (Qiagen) according to manufacturers’ instructions and a 2 ml aliquot of the
ﬁve-fold diluted cDNA from the reverse transcription reaction was used as
template in the subsequent qPCR assay (miScript SYBR Green PCR kit, Qiagen).
qPCR reaction master mix and programme settings were followed according to
manufacturers’ instructions except for the use of a 4 mM forward primer speciﬁc
to the hairpin sequence (OPMD hairpin primers are reported as Supplementary
Note 1).
Western blot. Lysates from in vitro experiments were prepared by homogenizing
cells in RIPA buffer containing: 0.15M NaCl, 0.1% SDS, 50mM Tris (pH 8), 2mM
EDTA and 10% Triton X–100 with protease inhibitor cocktail (Complete, Roche
Diagnostics). Muscle lysates were prepared by homogenizing tissue in RIPA
solution (NaCl 0.15M, HEPES 0.05M, NP-40 1%, sodium dehoxycholate 0.5%,
SDS 0.10%, EDTA 0.01M) with protease inhibitor cocktail. Proteins were separated
on 4–12% Bis-Tris gel (Invitrogen) and transferred onto a nitrocellulose membrane
(Hybond ECL membrane; Amersham Biosciences) for 1 h at 30V constant.
Membrane was blocked by incubation in 5% milk in 0.1M PBS, 0.2% Tween-20 for
1 h at room temperature (r.t.). Membrane was stained with primary antibodies
raised against PABPN1 (Abcam rabbit monoclonal, ab75855, 1/10,000, overnight
(ON)), Vinculin (Sigma-Aldrich mouse monoclonal SAB4200080, 1/10,000, ON),
GAPDH (Abcam mouse monoclonal ab9485, 1/2,500, ON), MYC-tag (Abcam
rabbit polyclonal, ab9106, 1/5,000, ON) or FLAG (F3165 Sigma monoclonal,
1/2,000 ON). Membranes were then incubated with appropriate secondary
antibodies conjugated either to the ﬂuorochrome 800 (Licor, 1:10,000, 1 h r.t.)
or to horseradish peroxidase . The Odyssey system (Licor) and the G:Box system
(Syngene) were used to detect the signals from the membranes. All uncropped
western blots included on the study are reported as Supplementary Fig. 7.
Histology and immunoﬂuorescence analysis. Muscles were cross-sectioned at
10mm thickness using a Bright OTF 5000 cryostat (Bright Instruments,
Huntingdon, UK). The tissue sections were placed on coated glass slides (VWR,
Lutterworth, UK) and stored at  80 C prior to use. The following antibodies were
used for immunohistochemical staining: anti-PABPN1 (rabbit monoclonal, diluted
1:100, Abcam ab75855, ON, 4 C), anti-neoMHC70 (rabbit polyclonal, 1:50, 1 h
r.t.), anti-Laminin (rat monoclonal; diluted 1:800; Sigma-Aldrich L0663, 1 h r.t.),
anti-ﬁbronectin (rabbit polyclonal, Dako 0245, 1:500, 1 h r.t.) or anti-collagen VI
(rabbit polyclonal, Abcam ab6588, 1:200, 1 h r.t.). Secondary antibodies were Alexa
ﬂuor (Molecular Probes) conjugated to 488 or 594 ﬂuorochromes. For nuclear
aggregates PABPN1 immunostaining, a published protocol21,24 was modiﬁed to
counterstain the sarcolemma with Laminin. Brieﬂy, the slides were ﬁxed in
paraformaldehyde 4% and soluble proteins were removed by incubating with KCl
buffer (1M KCl, 30mM HEPES, 65mM PIPES, 10mM EDTA, 2mM MgCl2,
pH 6.9) for 1 h at r.t. Sections were then blocked for 1 h with 1% normal goat serum
in 0.1M PBS, 0.1% Triton X-100 and then incubated overnight at 4 C with
PABPN1 primary antibody diluted in the same buffer. Slides were then incubated
with the anti-Laminin antibody (Sigma, rat monoclonal 1:800, 1 h r.t.). After
washings, sections were incubated with ﬂuorophore-conjugated secondary
antibodies. Slides were mounted with mounting medium vector containing
40,6-diamidino-2-phenylindole (DAPI; 3 mgml 1; Sigma-Aldrich Ltd.) to visualize
nuclei. The percentage of the area stained for collagen VI or Sirius red in
cryosections was measured by averaging the results of ﬁve randomly captured ﬁelds
( 20 magniﬁcation, covering most of the section) using NIH ImageJ analysis
software. The same programme was used to count the amount of INI in ﬁve
randomly captured ﬁelds and the number of centrally nucleated ﬁbres. All
immmunoﬂuorescence images were captured and digitized using identical
parameters of exposure, saturation and gamma-levels between specimens. Standard
protocols for haematoxylin and eosin (H&E) and Sirius red stainings were used to
calculate the percentage of centrally nucleated ﬁbres and to detect the area covered
by ﬁbrosis.
Statistical analysis. All data are presented as mean values±standard error of the
mean (mean±s.e.m.) and all n values represent biological replicates. GraphPad
Prism (version 4.0b; GraphPad Software, San Diego, CA, USA) was used for the
analyses. The same software was used to test for normal distribution of data
(Kolmogorov–Smirnov test) and to evaluate the variance between groups of data.
Statistical analyses were performed using the Student t-test, the one-way analysis of
variance with the Bonferroni post-hoc analysis or the chi-squared analysis.
A sample-size power analysis was not performed. A difference was considered to be
signiﬁcant at *Po0.05, **Po0.01 or ***Po0.001.
Data availability. Microarray data have been deposited in NCBI’s Gene
Expression Omnibus and are accessible through GEO Series accession number
GSE89996. All relevant data are available from the corresponding authors upon
reasonable request.
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